SG146673A1 - Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient - Google Patents
Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredientInfo
- Publication number
- SG146673A1 SG146673A1 SG200807030-2A SG2008070302A SG146673A1 SG 146673 A1 SG146673 A1 SG 146673A1 SG 2008070302 A SG2008070302 A SG 2008070302A SG 146673 A1 SG146673 A1 SG 146673A1
- Authority
- SG
- Singapore
- Prior art keywords
- diseases
- rejection
- graft
- allergic
- infection
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 2
- 230000000172 allergic effect Effects 0.000 abstract 2
- 208000010668 atopic eczema Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000002909 Aspergillosis Diseases 0.000 abstract 1
- 208000036641 Aspergillus infections Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004264855 | 2004-09-13 | ||
| JP2005127359 | 2005-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG146673A1 true SG146673A1 (en) | 2008-10-30 |
Family
ID=36060170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200807030-2A SG146673A1 (en) | 2004-09-13 | 2005-09-12 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8143404B2 (ja) |
| EP (2) | EP1790637B1 (ja) |
| JP (1) | JP4894518B2 (ja) |
| KR (1) | KR101231466B1 (ja) |
| CN (1) | CN101775013A (ja) |
| AR (1) | AR050643A1 (ja) |
| AU (1) | AU2005283326B2 (ja) |
| BR (1) | BRPI0515164A (ja) |
| CA (1) | CA2579501C (ja) |
| ES (1) | ES2457041T3 (ja) |
| IL (1) | IL181783A (ja) |
| MA (1) | MA28921B1 (ja) |
| MX (1) | MX2007002886A (ja) |
| NO (1) | NO20071342L (ja) |
| NZ (1) | NZ553696A (ja) |
| PE (2) | PE20060598A1 (ja) |
| RU (1) | RU2409565C2 (ja) |
| SG (1) | SG146673A1 (ja) |
| TW (1) | TWI400232B (ja) |
| WO (1) | WO2006030925A1 (ja) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2385040A1 (en) | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| JP2007523142A (ja) * | 2004-02-18 | 2007-08-16 | アストラゼネカ アクチボラグ | ベンズアミド誘導体、およびグルコキナーゼ活性化物質としてのそれらの使用 |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| WO2006030925A1 (ja) | 2004-09-13 | 2006-03-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| US20070066624A1 (en) * | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
| US8003642B2 (en) * | 2006-03-10 | 2011-08-23 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| EP2018380B1 (en) | 2006-05-19 | 2011-10-19 | Abbott Laboratories | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| CL2007003061A1 (es) | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| WO2009058921A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| WO2009058919A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| RS52712B (sr) | 2008-04-11 | 2013-08-30 | Janssen Pharmaceutica N.V. | Tiazolopiridin-2-iloksi-fenil i tiazolopirazin-2-iloksi-fenil amini kao modulatori leukotrien a4 hidrolaze |
| WO2010014913A1 (en) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| WO2010015849A2 (en) | 2008-08-04 | 2010-02-11 | Astrazeneca Ab | Therapeutic agents 414 |
| KR101660996B1 (ko) * | 2008-09-16 | 2016-09-28 | 넥타르 테라퓨틱스 | 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드 |
| WO2010054215A1 (en) | 2008-11-06 | 2010-05-14 | Ventirx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| AR076221A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
| AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
| MX2011012190A (es) | 2009-05-14 | 2011-12-08 | Janssen Pharmaceutica Nv | Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa. |
| CN102781933B (zh) * | 2009-08-18 | 2016-01-20 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| RU2016125705A (ru) | 2009-08-18 | 2018-12-04 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов |
| EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| KR20140131971A (ko) | 2012-03-13 | 2014-11-14 | 레스피버트 리미티드 | 신규 약학 제제 |
| AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| CN105308045B (zh) * | 2013-05-27 | 2017-05-17 | 豪夫迈·罗氏有限公司 | 新的3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物 |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| US11491157B2 (en) | 2018-01-31 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company Co Cork, IE | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV |
| WO2019206828A1 (en) | 2018-04-23 | 2019-10-31 | Janssen Sciences Ireland Unlimited Company | Heteroaromatic compounds having activity against rsv |
| AU2019382642B2 (en) | 2018-11-22 | 2025-05-29 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4603143A3 (en) * | 2018-12-28 | 2025-11-05 | Mitsubishi Tanabe Pharma Corporation | Crystal of pyrrolidine compound |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN120500335A (zh) * | 2022-12-28 | 2025-08-15 | 瑞瑟沃神经科学公司 | Ep2拮抗剂化合物 |
| WO2025034531A1 (en) * | 2023-08-04 | 2025-02-13 | The University Of Vermont And State Agricultural College | Small molecule allosteric modulator to pac1 receptor and uses thereof |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1063744A (en) | 1964-05-25 | 1967-03-30 | American Cyanamid Co | 4-substituted-4'-tertiary aminoalkoxy biphenyls |
| US5169855A (en) | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
| US5364865A (en) * | 1992-12-30 | 1994-11-15 | Sterling Winthrop Inc. | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
| IL118469A (en) | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
| US5994344A (en) * | 1996-03-28 | 1999-11-30 | Glaxo Wellcome Inc. | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| AU5803398A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| TR199901395T2 (xx) | 1996-12-19 | 1999-11-22 | Hoechst Marion Roussel, Inc. | Yeni karboksi ikameli siklik karboksamid t�revleri. |
| ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| EP1020445B1 (en) * | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Fused pyridine derivatives |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| JP4321737B2 (ja) | 1997-12-17 | 2009-08-26 | 塩野義製薬株式会社 | 新規ピリジン化合物 |
| CN1282243A (zh) | 1997-12-19 | 2001-01-31 | 武田药品工业株式会社 | 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物 |
| WO1999038514A1 (en) | 1998-02-02 | 1999-08-05 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| JP2002512957A (ja) | 1998-04-27 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | Ｃｃｒ−３受容体アンタゴニスト |
| EP1073434A1 (en) | 1998-04-27 | 2001-02-07 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| BR9912406A (pt) | 1998-07-28 | 2001-04-24 | Smithkline Beecham Corp | Compostos de anilida substituida e métodos |
| WO2000006085A2 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Compounds and methods |
| CA2338804A1 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Propenamides as ccr5 modulators |
| AU5301599A (en) * | 1998-08-20 | 2000-03-14 | Takeda Chemical Industries Ltd. | Quaternary ammonium salts and their use |
| WO2000021916A1 (fr) | 1998-10-15 | 2000-04-20 | Takeda Chemical Industries, Ltd. | Procede de preparation de derives d'amine |
| WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| JP3475177B2 (ja) | 1998-11-17 | 2003-12-08 | エフ．ホフマン−ラ ロシュ アーゲー | ４−アロイルピペリジンｃｃｒ−３受容体拮抗剤ｉｉｉ |
| JP3593037B2 (ja) | 1998-11-20 | 2004-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | ピロリジン誘導体ｃｃｒ−３受容体アンタゴニスト |
| EP1131290B1 (en) | 1998-11-20 | 2008-02-20 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
| WO2000034278A1 (en) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient |
| WO2000035877A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| CA2347769A1 (en) | 1998-12-18 | 2000-06-22 | Dean A. Wacker | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
| US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2346933A1 (en) | 1998-12-18 | 2000-06-22 | Dupont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| ATE302606T1 (de) | 1998-12-18 | 2005-09-15 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| WO2000035454A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1140086A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| WO2000037455A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| ATE264100T1 (de) | 1998-12-30 | 2004-04-15 | Smithkline Beecham Corp | Zusammensetzung und verfahren |
| SK9972001A3 (en) | 1999-01-13 | 2002-03-05 | Millennium Pharm Inc | Quinolizine derivative, pharmaceutical composition containing same and use thereof |
| WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| JP2002535256A (ja) | 1999-01-25 | 2002-10-22 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| JP2000309598A (ja) | 1999-02-25 | 2000-11-07 | Takeda Chem Ind Ltd | 多剤結合型新規化合物、その製造法および用途 |
| AU3389300A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| WO2000051608A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| AU3386400A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| US6362201B1 (en) | 1999-03-02 | 2002-03-26 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
| WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| US6506790B1 (en) | 1999-03-10 | 2003-01-14 | Smithkline Beecham Corporation | Compounds and methods |
| WO2000053600A1 (en) | 1999-03-11 | 2000-09-14 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| DE60028354T2 (de) | 1999-03-24 | 2007-02-08 | Anormed Inc., Langley | Chemokine rezeptor bindende heterozyklische verbindungen |
| EE200100502A (et) | 1999-03-26 | 2002-12-16 | Astrazeneca Ab | Ühendid |
| US6265434B1 (en) | 1999-04-06 | 2001-07-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6498161B1 (en) | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| EP1180513A4 (en) | 1999-04-28 | 2002-07-10 | Takeda Chemical Industries Ltd | Cyclic amide compounds, process for the preparation of the same and uses thereof |
| JP2002543126A (ja) | 1999-05-03 | 2002-12-17 | スミスクライン・ビーチャム・コーポレイション | Ｃｘｃｒ−４受容体アンタゴニスト−トロンボポエチン模倣物 |
| KR100439357B1 (ko) * | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체 |
| MXPA01011116A (es) | 1999-05-04 | 2002-06-04 | Schering Corp | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado. |
| IL145741A0 (en) * | 1999-05-04 | 2002-07-25 | Schering Corp | Piperazine derivatives useful as ccrs antagonists |
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| US6627651B1 (en) | 1999-05-07 | 2003-09-30 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| WO2000069815A1 (en) | 1999-05-13 | 2000-11-23 | Teijin Limited | Ureido-substituted cyclic amine derivatives and their use as drug |
| WO2000069432A1 (en) | 1999-05-18 | 2000-11-23 | Teijin Limited | Remedies or preventives for diseases in association with chemokines |
| WO2000073327A1 (en) | 1999-05-27 | 2000-12-07 | Celltek Biotechnologies Inc. | Chemokine receptor ccr3 antagonists |
| US6165261A (en) | 1999-06-10 | 2000-12-26 | Ergon, Inc. | Water-resistant gypsum composition |
| EP1200395B1 (en) | 1999-07-28 | 2006-03-29 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| JP4831906B2 (ja) | 1999-08-27 | 2011-12-07 | ケモセントリックス， インコーポレイテッド | Ｃｘｃｒ３機能を調節するための複素環式化合物および方法 |
| FR2798367B1 (fr) * | 1999-09-15 | 2001-11-23 | Valois Sa | Joint de soupape pour valve doseuse |
| KR100613176B1 (ko) | 1999-12-03 | 2006-08-17 | 오노 야꾸힝 고교 가부시키가이샤 | 트리아자스피로[5.5]운데칸 유도체 및 이들을유효성분으로 하는 약제 |
| GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| US6894063B2 (en) | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| JP2004509108A (ja) | 2000-09-14 | 2004-03-25 | シェーリング コーポレイション | 置換尿素神経ペプチドｙｙ５受容体アンタゴニスト |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| BR0116096A (pt) | 2000-12-11 | 2005-10-18 | Tularik Inc | Composto, composição farmacêutica, e, métodos para tratar uma condição ou doença inflamatória ou imune em um paciente, para tratar uma condição ou doença mediada por cxcr3 em um paciente, e para a modulação da função de cxcr3 em uma célula |
| GB0100102D0 (en) | 2001-01-03 | 2001-02-14 | Syngenta Participations Ag | Organic compounds |
| JP4612990B2 (ja) * | 2001-03-16 | 2011-01-12 | アボット・ラボラトリーズ | ヒスタミン−３受容体リガンドとしての新規アミンおよびそれらの治療的適用 |
| AU2002238947B2 (en) | 2001-03-19 | 2007-10-18 | Ono Pharmaceutical Co., Ltd. | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient |
| ES2342942T3 (es) * | 2001-03-29 | 2010-07-19 | Schering Corporation | Antagonistas de ccr5 utiles para el tratamiento del sida. |
| GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
| WO2002083628A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
| US6495569B1 (en) | 2001-04-19 | 2002-12-17 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| WO2002098869A2 (en) | 2001-06-05 | 2002-12-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| YU94103A (sh) | 2001-06-20 | 2006-03-03 | Pfizer Products Inc. | Novi derivati sulfonske kiseline |
| US6867221B2 (en) * | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
| US20050143372A1 (en) | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
| WO2003042174A1 (en) | 2001-11-14 | 2003-05-22 | Schering Corporation | Cannabinoid receptor ligands |
| TW200302717A (en) | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| WO2003101970A1 (en) | 2002-06-03 | 2003-12-11 | Smithkline Beecham Corporation | Imidazolium cxcr3 inhibitors |
| WO2003104230A1 (ja) | 2002-06-07 | 2003-12-18 | 協和醱酵工業株式会社 | 二環性ピリミジン誘導体 |
| US20050267114A1 (en) | 2002-09-18 | 2005-12-01 | Yoshikazu Takaoka | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| JP2006511500A (ja) * | 2002-10-30 | 2006-04-06 | メルク エンド カムパニー インコーポレーテッド | γ−アミノアミド系のケモカイン受容体活性調節剤 |
| US7342115B2 (en) | 2002-11-08 | 2008-03-11 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| JP2004256531A (ja) | 2003-02-07 | 2004-09-16 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および用途 |
| GB0305426D0 (en) | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| EP2385040A1 (en) * | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| AU2004233828B2 (en) * | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| JPWO2005023771A1 (ja) * | 2003-09-05 | 2006-11-02 | 小野薬品工業株式会社 | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| WO2006030925A1 (ja) * | 2004-09-13 | 2006-03-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| JP2007063268A (ja) | 2005-08-05 | 2007-03-15 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US20070066624A1 (en) | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
| US8003642B2 (en) | 2006-03-10 | 2011-08-23 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
-
2005
- 2005-09-12 WO PCT/JP2005/017209 patent/WO2006030925A1/ja not_active Ceased
- 2005-09-12 PE PE2005001056A patent/PE20060598A1/es not_active Application Discontinuation
- 2005-09-12 NZ NZ553696A patent/NZ553696A/en not_active IP Right Cessation
- 2005-09-12 EP EP05785808.6A patent/EP1790637B1/en not_active Expired - Lifetime
- 2005-09-12 US US11/662,639 patent/US8143404B2/en not_active Expired - Fee Related
- 2005-09-12 ES ES05785808.6T patent/ES2457041T3/es not_active Expired - Lifetime
- 2005-09-12 MX MX2007002886A patent/MX2007002886A/es active IP Right Grant
- 2005-09-12 AR ARP050103795A patent/AR050643A1/es not_active Application Discontinuation
- 2005-09-12 RU RU2007113814/04A patent/RU2409565C2/ru not_active IP Right Cessation
- 2005-09-12 EP EP12186689A patent/EP2546234A1/en not_active Withdrawn
- 2005-09-12 PE PE2008001407A patent/PE20090123A1/es not_active Application Discontinuation
- 2005-09-12 KR KR1020077008318A patent/KR101231466B1/ko not_active Expired - Fee Related
- 2005-09-12 CA CA2579501A patent/CA2579501C/en not_active Expired - Fee Related
- 2005-09-12 JP JP2006535240A patent/JP4894518B2/ja not_active Expired - Fee Related
- 2005-09-12 TW TW094131265A patent/TWI400232B/zh not_active IP Right Cessation
- 2005-09-12 BR BRPI0515164-3A patent/BRPI0515164A/pt not_active IP Right Cessation
- 2005-09-12 AU AU2005283326A patent/AU2005283326B2/en not_active Ceased
- 2005-09-12 SG SG200807030-2A patent/SG146673A1/en unknown
- 2005-09-12 CN CN201010126265A patent/CN101775013A/zh active Pending
-
2007
- 2007-03-07 IL IL181783A patent/IL181783A/en not_active IP Right Cessation
- 2007-03-12 NO NO20071342A patent/NO20071342L/no not_active Application Discontinuation
- 2007-04-06 MA MA29806A patent/MA28921B1/fr unknown
-
2011
- 2011-01-28 US US13/016,849 patent/US8410276B2/en not_active Expired - Fee Related
-
2012
- 2012-11-21 US US13/682,784 patent/US8604207B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG146673A1 (en) | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | |
| MXPA05009771A (es) | Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo. | |
| EA200870344A1 (ru) | Азотсодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента | |
| EP1541574A4 (en) | TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT | |
| EP3360554B1 (en) | Anti-hepatitis b virus agent | |
| van der Westhuyzen et al. | Pyrrolo [3, 4-c] pyridine-1, 3 (2 H)-diones: A novel antimycobacterial class targeting mycobacterial respiration | |
| CA2371583A1 (en) | Piperazine derivatives useful as ccr5 antagonists | |
| DK2155712T3 (en) | 3- (imidazolyl) pyrazolo [3,4-b] pyridines | |
| Darandale et al. | A novel amalgamation of 1, 2, 3-triazoles, piperidines and thieno pyridine rings and evaluation of their antifungal activity | |
| EP1661889A4 (en) | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES | |
| Kanawade et al. | Synthetic tactics of new class of 4-aminothieno [2, 3-d] pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents | |
| Laughlin et al. | The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-α) production | |
| EP1553084A4 (en) | Piperidin derivative, process for its preparation and use | |
| AU2022415492B2 (en) | Microbiocidal bicycle heterocyclic derivatives | |
| C. Heda et al. | Synthesis and Antimicrobial Activity of Some Derivatives of 5‐Substituted Indole Dihydropyrimidines | |
| Soliman et al. | Novel 6-phenylnicotinohydrazide derivatives: Design, synthesis and biological evaluation as a novel class of antitubercular and antimicrobial agents | |
| NO20082297L (no) | Piperazinderivater som er anvendelige som CCR5-antagonister | |
| Sriram et al. | Synthesis and Antimycobacterial Evaluation of Novel Phthalazin‐4‐ylacetamides Against log‐and Starved Phase Cultures | |
| JP2019533013A (ja) | 新しい抗微生物化合物、哺乳動物感染症の治療のためのそれらの使用及び新しい代謝メカニズム | |
| WO2003033506A1 (en) | Aminoborane acid derivative and proteasome inhibitory drug containing the same | |
| EP1621540A4 (en) | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF | |
| Kumar et al. | Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis | |
| Mallikarjuna et al. | Synthesis, anticancer and antituberculosis studies for [1-(4-chlorophenyl) Cyclopropyl](Piperazine-yl) Methanone derivates | |
| TH83338B (th) | อนุพันธ์เฮเทโรไซคลิคที่มีไนโตรเจน และยาที่มีสารเดียวกันนี้เป็นส่วนผสมแสดงฤทธิ์ | |
| TH83338A (th) | อนุพันธ์เฮเทโรไซคลิคที่มีไนโตรเจน และยาที่มีสารเดียวกันนี้เป็นส่วนผสมแสดงฤทธิ์ |